Purpose: In this study, a novel D-α-tocopheryl polyethylene glycol succinate (TPGS)
modified bovine serum albumin (BSA) nanoparticles (NPs) were developed for delivery of Anastrozole (ANZ) which is optimized by Box-Behnken design (BBD). Fabricated TPGS-ANZ-BSA NPs
were evaluated for their physicochemical and drug release characteristics.
Methods: TPGS-ANZ-BSA NPs were prepared by desolvation thermal gelation method and the effects of critical process parameter (CPP) which are BSA amount, TPGS concentration and stirring
speed on the critical quality attributes (CQA) such as % drug loading (%DL) and particle size were
studied using BBD. TPGS-ANZ-BSA NPs were characterized using different spectroscopic techniques including UV-Visible and FTIR is used to confirm the entrapment of ANZ in BSA. DSC
and PXRD revealed the amorphization of ANZ in the TPGS-ANZ-BSA NPs after freeze drying.
Scanning electron microscopy (SEM) analysis was performed for the surface morphology analyses
NPs. In vitro release studies were performed at pH 5.5 and pH 7.4 for 48h to mimic tumour microenvironment.
Results: The BBD optimized TPGS-ANZ-BSA NPs showed 107 nm particle size with %DL 8.5±
0.5%. The spectroscopic and thermal characterizations revealed the successful encapsulation of
ANZ inside the NPs. The TPGS-ANZ-BSA NPs were found to exhibit burst release at pH 5.5 and
sustained release at pH 7.4. The short-term stability displayed no significant changes in physical
properties TPGS-ANZ-BSA NPs at room temperature for a period one month.
Conclusion: The BBD optimized TPGS-ANZ-BSA nanoparticles showed enhanced physiochemical properties for ANZ and potential candidates for anticancer agent drugs delivery.